What Happened?
Shares of fertility benefits company Progyny (NASDAQ: PGNY) jumped 3.1% in the morning session after JPMorgan raised its price target on the company's stock. JPMorgan increased its price target to $25 from $23, while maintaining a "Neutral" rating on the shares. This move reflects an updated model of the company's performance and prospects. The positive sentiment from JPMorgan follows similar actions from other analysts recently. For instance, Cantor Fitzgerald also raised its price objective to $28 from $26 while reissuing an "overweight" rating. Additionally, Truist Financial lifted its target price on Progyny to $27 from $24. The series of price target increases from Wall Street firms suggests a more optimistic outlook on the stock's valuation, likely boosting investor confidence.
After the initial pop the shares cooled down to $23.04, up 1.8% from previous close.
Is now the time to buy Progyny? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Progyny’s shares are somewhat volatile and have had 12 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 9 days ago when the stock gained 3.1% on the news that continued positive momentum as the company reported stronger-than-expected second-quarter results and raised its full-year 2025 revenue and earnings guidance. The fertility benefits leader reported stronger-than-expected second-quarter results and raised its outlook for 2025. Progyny posted adjusted Q2 earnings of $0.48 per share, beating analyst estimates, on revenue of $332.9 million. Following the strong performance, the company boosted its full-year guidance, now projecting revenue of around $1.25 billion at the midpoint, up from its previous forecast of $1.21 billion. Management also raised its full-year adjusted earnings guidance to approximately $1.74 per share at the midpoint. This updated forecast highlights robust underlying growth driven by expanding demand for its fertility and family building benefits.
Progyny is up 29.9% since the beginning of the year, and at $23.04 per share, it is trading close to its 52-week high of $24.82 from September 2024. Investors who bought $1,000 worth of Progyny’s shares 5 years ago would now be looking at an investment worth $801.95.
Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
